Hemab Therapeutics/X
Aug 13, 2025, 09:21
VELORA Discover Study Now Enrolling: Advancing Care for Type 1 Von Willebrand Disease
Hemab Therapeutics shared an inviting post on X:
”Now enrolling people living with Type 1 Von Willebrand disease (VWD) into the VELORA Discover study.
This observational study aims to deepen understanding of Type 1 VWD and help lay the groundwork for future advances in care.
If you are living with Type 1 VWD or treating people who are, learn more about how to participate.”
You can direct your inquiries to [email protected].
Stay informed on all opportunities in the field of bleeding disorders with Hemostasis Today.
-
May 22, 2026, 10:23Rucha Patil: Insights from The National Haemophilia Conclave 2026
-
May 22, 2026, 10:11Narat Srivali: New Systematic Review and Meta-Analysis on Glucocorticoid Therapy and The Risk of VTE
-
May 22, 2026, 10:02Greta Mulders: Nursing Leadership in Haemophilia Gene Therapy
-
May 22, 2026, 08:45Dirk Sibbing: Ethnicity and Antiplatelet Therapy Outcomes in CCS
-
May 22, 2026, 08:35Jason Brandon: On Lyophilized Hemostatic Supplementation at Simmons Research Day 2026
-
May 22, 2026, 08:28Inconsistent D-Dimer Assay Reporting in VTE Studies – JTH
-
May 22, 2026, 08:21Vincent Jongkind: We Invite You to Participate in a Delphi Study for a Core Outcome Set in Acute Limb Ischemia
-
May 22, 2026, 07:46Jae Hyun Byun: Spatial Transcriptomics and the Emerging Complexity of Plaque Vulnerability
-
May 22, 2026, 07:45Thom Lysen: Tracking TTS Risk After COVID-19 Viral Vector-Based Vaccines